Skip to main content
. Author manuscript; available in PMC: 2019 Apr 5.
Published in final edited form as: Cell. 2018 Apr 5;173(2):371–385.e18. doi: 10.1016/j.cell.2018.02.060

Figure 6. Putative actionability across TCGA studies.

Figure 6

(A) Percentage of samples (y-axis) with at least 1 putatively actionable SNV/indel/CNV (orange), SNV/indel (blue), and CNV only (green) for each cancer type (x-axis) from the TARGET database. Sample size is also given for each cancer type in x-axis labels. Only 8,775 samples are represented due to limitations of copy number data. (B) Percentage of samples (y-axis) with a druggable mutation (missense, indel, frameshift, and nonsense) from DEPO in each cancer type (x-axis) at various stages of approval: FDA approved (red), Clinical Trials (blue), Case Reports (green), and Preclinical (orange). 9079 samples are represented. See also Figure S7.